Drugs.com New Drug ApprovalsOriginal article
Skyrizi (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
RegulatoryapprovedSkyriziPositive
AI Analysis
Summary
AbbVie announced FDA approval of Skyrizi (risankizumab-rzaa) for treating children six years and older with psoriatic disease, expanding the drug's pediatric indication.
Outcome Details
FDA approval for pediatric use in psoriatic disease for children six years and older
Importance:7/10
Sentiment:
0.85
FDA approvalpediatric indicationpsoriatic diseaselabel expansion
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on June 26, 2026 1:06 AM